Cryptococcosis due to Cryptococcus gattii in Germany from 2004-2013

International Journal of Medical Microbiology : IJMM
Ilka McCormick SmithVolker Rickerts

Abstract

The fungal pathogen Cryptococcus gattii was considered to be restricted to tropic and sub- tropic regions. A recent outbreak in North America due to isolates belonging to molecular type VG II, affecting mostly non-immunocompromised hosts, documented the potential public health impact of this fungal pathogen also in temperate regions. Surveillance of these infections in Germany is challenging, as cryptococcosis is not notifiable and often C. gattii is diagnostically not distinguished from the more prevalent Cryptococcus neoformans. We used hospital discharge data and identified cryptococcal isolates received by the German cryptococcosis reference laboratory at the species level to gain insights into the epidemiology of C. gattii-infections in Germany between 2004 and 2013. Between 49 and 60 (Median 57) hospitalizations for cryptococcosis are documented per year. Between 5 and 28 (Median 14) isolates were received at the reference laboratory per year. Among 155 single patient isolates, four C. gattii (3%) of the molecular types VGI and VG III were identified from patients with meningoencephalitis, including one interspecies hybrid. Patient histories and molecular typing suggest that half of the infections were acquired abroad. On...Continue Reading

References

Aug 1, 1987·Zentralblatt Für Bakteriologie, Mikrobiologie, Und Hygiene. Series A, Medical Microbiology, Infectious Diseases, Virology, Parasitology·F StaibA Blisse
Apr 20, 2004·AIDS·Françoise DromerUNKNOWN French Cryptococcosis Study Group
May 16, 2006·FEMS Yeast Research·Marjan BoversTeun Boekhout
Feb 2, 2010·Emerging Infectious Diseases·Eleni GalanisUNKNOWN British Columbia Cryptococcus gattii Working Group
Sep 24, 2011·Medical Mycology·Julie HarrisTom Chiller
Oct 22, 2011·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·J R HarrisT Chiller
Jan 21, 2012·Emerging Infectious Diseases·Anuradha ChowdharyJacques F Meis
Sep 29, 2012·Emerging Infectious Diseases·Ferry HagenTeun Boekhout
Mar 15, 2013·Molecular Biology and Evolution·Barry G Hall
Jul 5, 2013·Journal of Clinical Microbiology·Xiaobo FengZhirong Yao
Sep 21, 2013·Emerging Infectious Diseases·Julie R HarrisBenjamin J Park

❮ Previous
Next ❯

Citations

Sep 14, 2015·International Journal of Medical Microbiology : IJMM·Ulrich VogelMary Slack
Jun 1, 2018·The Journal of International Medical Research·Hui DengXinying Xue
Mar 23, 2019·Clinical Transplantation·John W BaddleyUNKNOWN AST Infectious Diseases Community of Practice
Jan 23, 2020·Genes·Himeshi SamarasingheTimothy Y James
Dec 5, 2016·Medical Mycology·Navaporn WorasilchaiAriya Chindamporn
Mar 30, 2019·Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz·Volker Rickerts
May 5, 2021·Environmental Microbiology Reports·Massimo Cogliati
Jun 18, 2021·Respiratory Medicine·D WilmesN Kanaan

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.